The threat of additional tariffs looms high, intco medical technology's stock price drops by 20%, What are the prospects for its North American layout?
①Today, Intco Medical Technology's stock fell 20 centimeters in the intraday trading session. An employee from the securities department of Intco Medical Technology stated, 'This is because the United States announced the impact of increasing tariffs on some Chinese commodities under Section 301.' ②The employee said that the proportion of the U.S. market in the company's revenue is about 35%, which may pose challenges to the company's performance in the short term. However, the overall potential of the U.S. market is still significant, and the company still plans to increase its efforts to expand into the North American market.
The second largest fine in the payment industry this year has been issued, with Youzan Payment being heavily fined 27.87 million yuan, while Lakala, Du Xiaoman, and others have been "double punished".
The Beijing branch of the People's Bank of China revealed five penalty decisions against payment institutions on September 10 in one breath. Among them, Youzan Pay was fined 27.87 million yuan, setting the second largest penalty in the payment industry this year, and rare in that both general managers were fined simultaneously. Industry insiders said that industry regulation is becoming increasingly detailed, and complete records are required for everything from service agreement formats to transaction information. From the perspective of regulatory trends, the dual-penalty system in the payment field continues to be implemented.
In the second quarter, Huawei ranked first in global wrist-wearing market shipments, and smart wearable devices may become a new frontier for AI implementation.
1. According to IDC data, Huawei shipped 8.883 million units in the global wearable device market in the second quarter of 2024, with 5.965 million units shipped in China, becoming the top player in both the global and Chinese wearable markets. 2. Shanxi believes that leading domestic consumer electronics manufacturers are bullish on the prospects of wearable devices. With the continuous maturation of edge AI technology, wearable devices will become a new outlet for AI applications.
The latest holding positions of the retirement fund have been exposed: In the second quarter, there were 61 new stocks in the top ten shareholders list, with Zhejiang Weixing Industrial Development and other stocks held by 2 shareholders.
① With the completion of the semi-annual report disclosure of listed companies, the top ten circulating shareholders of 188 stocks in the retirement fund appeared frequently; ② Among them, among the top ten circulating shareholders of 61 new stocks, Zhejiang Weixing Industrial Development, National Investment Intelligence and other 5 stocks each obtained 2 new shareholdings from the retirement fund; ③ Attached is the number of new shareholding institutions and A-share list in the second quarter of the retirement fund (see attached table).
Gross margin halved and investment income is poor luoyang xinqianglian slewing bearing H1 turned to a loss|interpretations
①The decline in revenue year-on-year, the stock price of the investment target dropped, and the assets shrank, causing the star stock luoyang xinqianglian to report a worsened loss in the mid-year report compared to the first quarter; ②In response, the company stated that it will further increase new product technology research and development innovation, and deepen its market expansion and optimization of the supply chain management.
Core business revenue and gross margin both declined, with Apichope Pharmaceutical's net profit in the first half of the year significantly reduced. Interpreting financial reports.
Due to changes in the external market environment and internal business adjustments, apichope pharmaceutical's H1 revenue and net profit have both declined. Previously, the company was punished by the Medical Insurance Bureau due to false labeling, not only resulting in the return of a large amount of funds, but also the suspension of its qualification to participate in national procurement for 6 months.